Cancer News
OncoLink Cancer News - HealthDay


Combination Therapy Can Cut Prostate Cancer Death Risk

-- Jeff Muise

Thursday, July 16, 2009

THURSDAY, July 16 (HealthDay News) -- The risk of death from prostate cancer is lower for patients treated with brachytherapy supplemented by external-beam radiation therapy (EBRT) and androgen suppression therapy (AST) than it is for those treated with brachytherapy alone, according to a study published online July 13 in the Journal of Clinical Oncology.

Anthony V. D'Amico, M.D., of Brigham and Women's Hospital in Boston, and colleagues evaluated the risk of prostate cancer mortality for high-risk patients treated with brachytherapy alone, in combination with EBRT alone or AST alone, or a combination of all three therapies. The researchers compared outcomes in 1,342 men with prostate-specific antigen levels of more than 20 ng/mL and disease rated as T3 or 4 or with a Gleason score of eight to 10. Multivariate regression analysis was used to estimate the risk of death in men in the treatment groups.

At median follow-up of 5.1 years, the researchers found that patients treated with brachytherapy and both EBRT and AST had a lower mortality risk (adjusted hazard ratio, 0.32) compared with those treated with brachytherapy alone. However, there was no risk improvement for patients treated with brachytherapy and only one of the supplemental treatments compared to brachytherapy alone.

"These data should heighten awareness among physicians that, to maximize curability in men with high-risk prostate cancer treated using brachytherapy, the addition of both supplemental AST and EBRT to brachytherapy seems necessary," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.


I Wish You Knew

What is Photodynamic Therapy and how is it used in cancer care?

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More